Elicio Therapeutics reports FY2025 net loss of $39.5M; Phase 2 PDAC trial DFS readout expected 1H 2026

Elicio Therapeutics, Inc.

Net loss for 2025 was $39.5M ($2.58 per share), compared to $51.9M ($4.25) in 2024.
R&D expense decreased to $24.9M from $33.7M; G&A expense increased to $12.8M from $11.3M.
Cash and equivalents $18.6M as of Dec 31, 2025; runway into Q3 2026 beyond expected Phase 2 DFS analysis.
Phase 2 AMPLIFY-7P trial in PDAC: fewer progressions and deaths observed than projected; primary DFS analysis on track for 1H 2026.
Raised net ~$4.9M in Q4 2025 and ~$6.3M in Q1 2026 via at-the-market program; appointed Marc J. Wolfgang as CTO.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Elicio Therapeutics, Inc. reported the year ended December 31, 2025 results: net income $39.5 million, EPS $2.58.

Period: the year ended December 31, 2025
Net income: $39.5 million
EPS: $2.58
Result: reported results

Exact text from the filing

Net loss for 2025 was $39.5 million, compared to $51.9 million for 2024. Net loss for 2025 includes $1.9 million of non-cash other expense resulting from the change in fair value of the warrant liability. Net loss per share for 2025 was $2.58, compared to $4.25 for 2024.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Elicio Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001601485-26-000026

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.